NEW YORK – New data presented over the weekend at the American Society of Clinical Oncology's virtual annual meeting, has added to growing evidence that genomic sequencing, in particular liquid biopsy tests, can identify actionable alterations in patients with cancers of unknown primary (CUP).
Adding to this, retrospective evidence presented at the meeting showed that at least some of these tumors may respond to targeted treatments, while other studies illustrated the challenges of implementing precision medicine, including obtaining the drugs indicated by genomic profiling tests.